NASDAQ:ACERAcer Therapeutics Stock Price, Forecast & News

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ACER stock has decreased by 8.9% and is now trading at $3.08. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acer Therapeutics.

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Acer Therapeutics.

Acer Therapeutics Inc (NASDAQ:ACER) released its quarterly earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.09. View Acer Therapeutics' earnings history.

5 brokerages have issued 12 month target prices for Acer Therapeutics' shares. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' share price to reach $22.33 in the next year. This suggests a possible upside of 625.1% from the stock's current price. View analysts' price targets for Acer Therapeutics.

News headlines about ACER stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acer Therapeutics earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutAcer Therapeutics.

Acer Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 449,900 shares, an increase of 7.3% from the April 30th total of 419,400 shares. Based on an average daily trading volume, of 85,800 shares, the short-interest ratio is currently 5.2 days. Approximately 9.0% of the company's stock are sold short. View Acer Therapeutics' Current Options Chain.

Some companies that are related to Acer Therapeutics include Savara (SVRA), GlycoMimetics (GLYC), Axovant Gene Therapies (AXGT), Catabasis Pharmaceuticals (CATB), Theratechnologies (THERF), AVEO Pharmaceuticals (AVEO), SUMMIT THERAPEU/S (SMMT), OASMIA PHARMACE/ADR (OASM), InflaRx (LUMO), Recro Pharma (REPH), Checkpoint Therapeutics (CKPT), Eton Pharmaceuticals (ETON), ESSA Pharma (EPIX), AcelRx Pharmaceuticals (ACRX) and Genprex (GNPX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Amarin (AMRN), Anavex Life Sciences (AVXL), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Arena Pharmaceuticals (ARNA) and Crispr Therapeutics (CRSP).

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (1.35%), Federated Hermes Inc. (0.89%), Parametric Portfolio Associates LLC (0.71%), Bank of New York Mellon Corp (0.21%) and WINTON GROUP Ltd (0.16%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View institutional ownership trends for Acer Therapeutics.

ACER stock was sold by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC, and WINTON GROUP Ltd. View insider buying and selling activity for Acer Therapeutics.

ACER stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., State Street Corp, and Bank of New York Mellon Corp. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm, and Steve Aselage. View insider buying and selling activity for Acer Therapeutics.

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $3.08.

Acer Therapeutics has a market capitalization of $31.57 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.

The official website for Acer Therapeutics is www.acertx.com.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]